GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arbutus Biopharma Corp (STU:I9DN) » Definitions » Institutional Ownership

Arbutus Biopharma (STU:I9DN) Institutional Ownership : 17.95% (As of May. 27, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Arbutus Biopharma Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Arbutus Biopharma's institutional ownership is 17.95%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Arbutus Biopharma's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Arbutus Biopharma's Float Percentage Of Total Shares Outstanding is 78.72%.


Arbutus Biopharma Institutional Ownership Historical Data

The historical data trend for Arbutus Biopharma's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arbutus Biopharma Institutional Ownership Chart

Arbutus Biopharma Historical Data

The historical data trend for Arbutus Biopharma can be seen below:

2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30
Institutional Ownership 18.83 18.76 19.17 17.33 17.37 18.39 18.30 18.31 18.08 17.95

Arbutus Biopharma Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Arbutus Biopharma (STU:I9DN) Business Description

Traded in Other Exchanges
Address
701 Veterans Circle, Warminster, PA, USA, 18974
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.

Arbutus Biopharma (STU:I9DN) Headlines

No Headlines